Methamphetamine-induced vascular changes lead to striatal hypoxia and dopamine reduction

NeuroReport

Volumn 22, Issue 17, 2011, Pages 923-928

  Kousik, Sharanya M ^a   Graves, Steven M ^a   Napier, T Celeste ^a   Zhao, Chaohui ^b   Carvey, Paul M ^a  

^a RUSH UNIVERSITY   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

blood brain barrier; cerebral vasculature; hypoxia inducible factor 1 ; methamphetamine; Parkinson's disease

Indexed keywords

DOPAMINE; METHAMPHETAMINE; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN BLOOD VESSEL; BRAIN PERFUSION; CONTROLLED STUDY; CORPUS STRIATUM; HYPOXIA; MALE; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; RISK FACTOR; VASOCONSTRICTION;

AMPHETAMINE-RELATED DISORDERS; ANIMALS; BIOLOGICAL MARKERS; CEREBROVASCULAR DISORDERS; CORPUS STRIATUM; DOPAMINE; FLUORESCEIN-5-ISOTHIOCYANATE; HYPOXIA, BRAIN; MALE; METHAMPHETAMINE; PARKINSON DISEASE, SECONDARY; RATS; RATS, SPRAGUE-DAWLEY;

EID: 80855132582     PISSN: 09594965     EISSN: 1473558X     Source Type: Journal    
DOI: 10.1097/WNR.0b013e32834d0bc8     Document Type: Article

References (25)

1. Yamamoto BK, Moszczynska A, Gudelsky GA. Amphetamine toxicities: Classical and emerging mechanisms. Ann N Y Acad Sci 2010; 1187: 101-121.
2. Callaghan RC, Cunningham JK, Sajeev G, Kish SJ. Incidence of Parkinson's disease among hospital patients with methamphetamine-use disorders. Mov Disord 2010; 25:2333-2339.
3. Volz TJ, Fleckenstein AE, Hanson GR. Methamphetamine-induced alterations in monoamine transport: Implications for neurotoxicity, neuroprotection and treatment. Addiction 2007; 102 (Suppl 1):44-48. (Pubitemid 46328209)
4. Wilson JM, Kalasinsky KS, Levey AI, Bergeron C, Reiber G, Anthony RM, et al. Striatal dopamine nerve markers in human, chronic methamphetamine users. Nature Medicine 1996; 2:699-703. (Pubitemid 26191961)
5. Volkow ND, Chang L, Wang GJ, Fowler JS, Leonido-Yee M, Franceschi D, et al. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry 2001; 158: 377-382. (Pubitemid 32205193)
6. Thrash B, Karuppagounder SS, Uthayathas S, Suppiramaniam V, Dhanasekaran M. Neurotoxic effects of methamphetamine. Neurochem Res 2010; 35:171-179.
7. Prudencio C, Abrantes B, Lopes I, Tavares MA. Structural and functional cellular alterations underlying the toxicity of methamphetamine in rat retina and prefrontal cortex. Ann N Y Acad Sci 2002; 965:522-528. (Pubitemid 34721999)
8. Ouchi Y, Yoshikawa E, Sekine Y, Futatsubashi M, Kanno T, Ogusu T, et al. Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann Neurol 2005; 57:168-175. (Pubitemid 40179853)
9. Riddle EL, Fleckenstein AE, Hanson GR. Mechanisms of methamphetamineinduced dopaminergic neurotoxicity. AAPS J 2006; 8:E413-E418.
10. Kuhn DM, Francescutti-Verbeem DM, Thomas DM. Dopamine quinones activate microglia and induce a neurotoxic gene expression profile: Relationship to methamphetamine-induced nerve ending damage. Ann N Y Acad Sci 2006; 1074:31-41. (Pubitemid 44532808)
11. Yamamoto BK, Raudensky J. The role of oxidative stress, metabolic compromise, and inflammation in neuronal injury produced by amphetaminerelated drugs of abuse. J Neuroimm Pharm 2008; 3:203-217.
12. Kiyatkin EA, Brown PL, Sharma HS. Brain edema and breakdown of the blood-brain barrier during methamphetamine intoxication: Critical role of brain hyperthermia. Eur J Neurosci 2007; 26:1242-1253. (Pubitemid 47346759)
13. McDaid J, Graham MP, Napier TC. Methamphetamine-induced sensitization differentially alters pCREB and DFosB throughtout the limbic circuit of the mammalian brain. Molr Pharmacol 2006; 70:2064-2074. (Pubitemid 44771922)
14. Sharma HS, Kiyatkin EA. Rapid morphological brain abnormalities during acute methamphetamine intoxication in the rat: An experimental study using light and electron microscopy. J Chem Neuroanat 2009; 37:18-32.
15. Graves SM, Napier TC. Mirtazapine alters cue-associated methamphetamine seeking in rats. Biol Psychiatry 2011; 69:275-281.
16. Carvey PM, Zhao CH, Hendey B, Lum H, Trachtenberg J, Desai BS, et al. 6-Hydroxydopamine-induced alterations in blood-brain barrier permeability. Eur J Neurosci 2005; 22:1158-1168. (Pubitemid 41395380)
17. Sakoori K, Murphy NP. Reduced degeneration of dopaminergic terminals and accentuated astrocyte activation by high dose methamphetamine administration in nociceptin receptor knock out mice. Neurosci Lett 2010; 469:309-313.
18. Carvey PM, Hendey B, Monahan AJ. The blood-brain barrier in neurodegenerative disease: A rhetorical perspective. J Neurochem 2009; 111:291-314.
19. Jiang Y,Wu J, Keep RF, Hua Y, Hoff JT, Xi G. Hypoxia-inducible factor-1alpha accumulation in the brain after experimental intracerebral hemorrhage. J Cereb Blood Flow Metab 2002; 22:689-696. (Pubitemid 34596461)
20. Hamel E. Perivascular nerves and the regulation of cerebrovascular tone. J Appl Physiol 2006; 100:1059-1064. (Pubitemid 43671565)
21. Belaidi E, Joyeux-Faure M, Ribuot C, Launois SH, Levy P, Godin-Ribuot D. Major role for hypoxia inducible factor-1 and the endothelin system in promoting myocardial infarction and hypertension in an animal model of obstructive sleep apnea. J Am Coll Cardiol 2009; 53:1309-1317.
22. Van den Buuse M, Webber KM. Endothelin and dopamine release. Prog Neurobiol 2000; 60:385-405.
23. Kohzuma M, Kataoka Y, Koizumi S, Shibaguchi H, Nakashima MN, Yamashita K, et al. ETB receptor involvement in stimulatory and neurotoxic action of endothelin on dopamine neurones. Neuroreport 1994; 5:2653-2656.
24. Iyo M, Sekine Y, Mori N. Neuromechanism of developing methamphetamine psychosis: A neuroimaging study. Ann N Y Acad Sci 2004; 1025: 288-295. (Pubitemid 39643874)
25. Chung YA, Peterson BS, Yoon SJ, Cho SN, Chai S, Jeong J, et al. In vivo evidence for long-term CNS toxicity, associated with chronic binge use of methamphetamine. Drug Alcohol Depend 2010; 111:155-160.